Cargando…
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285523/ https://www.ncbi.nlm.nih.gov/pubmed/35844776 http://dx.doi.org/10.2147/JAA.S358321 |
| _version_ | 1784747802888241152 |
|---|---|
| author | O’Reilly, Emily Casey, Deborah Ibrahim, Hisham McGrath, Alice McHugh, Tomás Vairamani, Punitha Murphy, Jill Plant, Barry Murphy, Desmond M |
| author_facet | O’Reilly, Emily Casey, Deborah Ibrahim, Hisham McGrath, Alice McHugh, Tomás Vairamani, Punitha Murphy, Jill Plant, Barry Murphy, Desmond M |
| author_sort | O’Reilly, Emily |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9285523 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92855232022-07-16 Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy O’Reilly, Emily Casey, Deborah Ibrahim, Hisham McGrath, Alice McHugh, Tomás Vairamani, Punitha Murphy, Jill Plant, Barry Murphy, Desmond M J Asthma Allergy Research Letter Dove 2022-07-11 /pmc/articles/PMC9285523/ /pubmed/35844776 http://dx.doi.org/10.2147/JAA.S358321 Text en © 2022 O’Reilly et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Research Letter O’Reilly, Emily Casey, Deborah Ibrahim, Hisham McGrath, Alice McHugh, Tomás Vairamani, Punitha Murphy, Jill Plant, Barry Murphy, Desmond M Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title | Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title_full | Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title_fullStr | Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title_full_unstemmed | Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title_short | Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy |
| title_sort | real-world clinical outcomes in asthmatic patients switched from omalizumab to anti-interleukin-5 therapy |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285523/ https://www.ncbi.nlm.nih.gov/pubmed/35844776 http://dx.doi.org/10.2147/JAA.S358321 |
| work_keys_str_mv | AT oreillyemily realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT caseydeborah realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT ibrahimhisham realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT mcgrathalice realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT mchughtomas realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT vairamanipunitha realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT murphyjill realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT plantbarry realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy AT murphydesmondm realworldclinicaloutcomesinasthmaticpatientsswitchedfromomalizumabtoantiinterleukin5therapy |